Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

154
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
154
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

153
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
153
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

356
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
356
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

175
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
175
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

195
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
195
Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

171
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
171

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Current and future aspects of IBD research and treatment: The 2022 perspective.

Frontiers in gastroenterology (Lausanne, Switzerland)·2026
Same author

MMW Fortschritte der Medizin·2025
Same author

To STRIDE or not to STRIDE: a critique of "treat to target" in ulcerative colitis.

Expert review of gastroenterology & hepatology·2024
Same author

Dysbiosis in inflammatory bowel diseases: egg, not chicken.

Frontiers in medicine·2024
Same author

Are Internet Information Sources Helpful for Adult Crohn's Disease Patients Regarding Nutritional Advice?

Journal of clinical medicine·2024
Same author

To STRIDE or not to STRIDE: a critique of "treat to target" in Crohn´s disease.

Expert review of gastroenterology & hepatology·2023

Related Experiment Video

Updated: Jul 22, 2025

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.3K

Prioritization in inflammatory bowel disease therapy.

Klaus R Herrlinger1, Eduard F Stange2

  • 1Internal Medicine I, Asklepios Klinik, Hamburg, Germany.

Expert Review of Gastroenterology & Hepatology
|July 22, 2023
PubMed
Summary
This summary is machine-generated.

This review offers guidance on selecting optimal therapies for complex inflammatory bowel disease (IBD) cases, including Crohn's disease and ulcerative colitis. It prioritizes specific biologic drugs and JAK inhibitors for challenging treatment scenarios.

Keywords:
Crohn´s diseaseJAK-inhibitorsbiologicalstherapyulcerative colitis

More Related Videos

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.5K
In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

5.5K

Related Experiment Videos

Last Updated: Jul 22, 2025

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.3K
Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
07:38

Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing

Published on: September 13, 2016

8.5K
In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

5.5K

Area of Science:

  • Gastroenterology
  • Immunology
  • Pharmacology

Background:

  • Current inflammatory bowel disease (IBD) guidelines often recommend a step-by-step approach using conventional therapies like aminosalicylates or steroids.
  • These guidelines may not adequately prioritize advanced treatments such as biologic drugs and Janus kinase (JAK) inhibitors for complicated IBD cases.

Purpose of the Study:

  • To provide an evidence-based aid for optimizing and personalizing therapy decisions in Crohn's disease (CD) and ulcerative colitis (UC), particularly in difficult-to-treat patients.
  • To analyze current literature to guide the selection of advanced therapies for complex IBD management.

Main Methods:

  • A continuous literature review was conducted using PubMed.
  • Key search terms included 'Crohn's disease' and 'ulcerative colitis' to identify relevant publications.

Main Results:

  • For steroid-refractory Crohn's disease, initial treatment with combined infliximab plus azathioprine or risankizumab is recommended, followed by ustekinumab or adalimumab if initial therapy fails.
  • For steroid-refractory ulcerative colitis, first-line treatment should involve infliximab plus azathioprine or upadacitinib, with filgotinib, tofacitinib, or ustekinumab as second-line options.
  • For steroid-dependent courses in both CD and UC, azathioprine or vedolizumab are suggested first-line, with infliximab or JAK inhibitors as second-line options.

Conclusions:

  • The data suggest specific therapeutic sequences for managing steroid-refractory and steroid-dependent IBD.
  • These evidence-based conclusions can assist clinicians in making individualized treatment decisions for patients with complex IBD.
  • Personalized therapy selection is crucial for improving outcomes in challenging IBD cases.